Blood Test Can Determine Liver Disease Progression
By LabMedica International staff writers Posted on 22 Jun 2022 |
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide and is estimated to affect about 30% of the European population. Chronic non-alcoholic fatty liver disease can develop into irreversible liver cirrhosis, which can only be cured by liver transplantation. Therefore, it is particularly important to identify patients with non-alcoholic fatty liver disease early on. Now, researchers have identified the role of a specific subtype of macrophages (white blood cells) in progressive NAFLD. As part of the immune system, these cells have a protective function against fibrosis and liver cirrhosis. At the same time, they are useful as biomarkers of liver disease progression as they can be measured by a blood test.
The pathogenesis (development) of NAFLD, especially advanced steatohepatitis (NASH, also: non-alcoholic fatty liver hepatitis), is associated with profound changes in immune cells in the liver. Recently, the increased accumulation of a subtype of macrophages that express high levels of the receptor TREM2 has been described in fatty liver disease. However, the role of TREM2-positive macrophages in non-alcoholic fatty liver disease was hitherto unknown. Now, researchers at Medical University Vienna (Vienna, Austria) have shown in an animal model that these specific macrophages have a protective function in fibrosis - a precursor to liver cirrhosis. These cells are found in greater numbers in the affected areas of the liver upon NAFLD-associated liver inflammation, where they accumulate particularly in areas of cellular damage and fibrosis.
TREM2 exists both as a membrane receptor on cells as well as a soluble form (sTREM2) that is detectable in blood. The role of this soluble form in the immune system is not yet clear. However, the researchers discovered that it is useful in patients for determining the current status of the disease and helps to distinguish between the different stages of fatty liver hepatitis much better than previously known biomarkers used in clinical practice. The researchers also demonstrated in bone marrow transplantation models that hematopoietic TREM2 deficiency prevents efficient fat storage and breakdown of excess connective tissue (extracellular matrix), leading to increased steatohepatitis, cell death and fibrosis. Hence, TREM2-positive macrophages fulfill an important protective function in NAFLD, where they prevent fat accumulation, inflammatory processes and progression of the disease to liver fibrosis.
"It may be possible to develop new therapeutic approaches to treat fatty liver hepatitis by enhancing this protective function of TREM2-positive macrophages," said Florentina Porsch, co-first author of the study.
"The soluble form of TREM2 is an excellent biomarker for identifying and staging advanced liver disease, which can progress from fatty liver disease to incurable cirrhosis if left untreated," added first author Tim Hendrikx from MedUni Vienna's Department of Laboratory Medicine.
Related Links:
Medical University Vienna
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing